ArticleClinical cancer research : an official journal of the American Association for Cancer Research2023
Advanced Age in Humans and Mouse Models of Glioblastoma Show Decreased Survival from Extratumoral Influence.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Glioblastoma immunotherapy in the context of the aging immune system: a systematic review and meta-analysis.Journal of neuro-oncology · 2026Pooled it
- Astrocyte-associated immunosuppressive programs in brain tumors: a STAT3-centered perspective.Cancer metastasis reviews · 2026Review
- Survival and function in elderly patients with GBM: the role of surgical resection with contemporary multimodal therapy.Journal of neuro-oncology · 2026Article
- Revolutionizing cancer treatment with senotherapeutics: a current perspective.Cancer chemotherapy and pharmacology · 2026Review
- Review
- Multilayered insights into the full spectrum of diffuse gliomas: a novel prognostic evaluation model.Discover oncology · 2025Article
- Effects of aging on anticancer therapy in murine cancer models.Cancer metastasis reviews · 2025Review
- A deep learning model to predict glioma recurrence using integrated genomic and clinical data.Communications medicine · 2025Article
- The clinical impact of EGFR alterations in elderly glioblastoma patients: results from a real-life cohort.Journal of neuro-oncology · 2025Article
- Immune therapeutic strategies for the senescent tumor microenvironment.British journal of cancer · 2025Review
- Is modulation of immune checkpoints on glioblastoma-infiltrating myeloid cells a viable therapeutic strategy?Neuro-oncology · 2025Review
- Immunotherapy in Glioblastoma: An Overview of Current Status.Clinical pharmacology : advances and applications · 2025Review
- All-trans retinoic acid inhibits glioblastoma progression and attenuates radiation-induced brain injury.JCI insight · 2024Article
- In vivo mouse models for adult brain tumors: Exploring tumorigenesis and advancing immunotherapy development.Neuro-oncology · 2024Review
- Article
- Pediatric glioma immune profiling identifies TIM3 as a therapeutic target in BRAF fusion pilocytic astrocytoma.The Journal of clinical investigation · 2024Article
- Immune Assessment Today: Optimizing and Standardizing Efforts to Monitor Immune Responses in Cancer and Beyond.Cancers · 2024Article
- The immunological landscape of peripheral blood in glioblastoma patients and immunological consequences of age and dexamethasone treatment.Frontiers in immunology · 2024Article
- Natural language processing algorithms identify wild-type isocitrate dehydrogenase gliomas in electronic health records.Neuro-oncology advancesArticle
- Age-dependent glioma progression and functional decline in a syngeneic murine model: Host vulnerabilities and opportunities for targeted intervention.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors at 13 institutions in 2 countries.
Funding
Abstract
purposeGlioblastoma (GBM) is the most common aggressive primary malignant brain tumor in adults with a median age of onset of 68 to 70 years old. Although advanced age is often associated with poorer GBM patient survival, the predominant source(s) of maladaptive aging effects remains to be established. Here, we studied intratumoral and extratumoral relationships between adult patients with GBM and mice with brain tumors across the lifespan. EXPERIMENTAL
designElectronic health records at Northwestern Medicine and the NCI SEER databases were evaluated for GBM patient age and overall survival. The commercial Tempus and Caris databases, as well as The Cancer Genome Atlas were profiled for gene expression, DNA methylation, and mutational changes with varying GBM patient age. In addition, gene expression analysis was performed on the extratumoral brain of younger and older adult mice with or without a brain tumor. The survival of young and old wild-type or transgenic (INK-ATTAC) mice with a brain tumor was evaluated after treatment with or without senolytics and/or immunotherapy.
resultsHuman patients with GBM ≥65 years of age had a significantly decreased survival compared with their younger counterparts. While the intra-GBM molecular profiles were similar between younger and older patients with GBM, non-tumor brain tissue had a significantly different gene expression profile between young and old mice with a brain tumor and the eradication of senescent cells improved immunotherapy-dependent survival of old but not young mice.
conclusionsThis work suggests a potential benefit for combining senolytics with immunotherapy in older patients with GBM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.